









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on February 2024

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil this month				
2) New Requests				
Secukinumab	RED			HUTH- application for TA935
Tirezapatide	AMB 1			HUTH- application for TA924
Semaglutide	RED			HUTH- application for TA875- for use within HUTH bariatric service
Anthelios	GREEN			Within ACBS criteria

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
3) New formulations & extensions to use				
Nil this month				
4) Products considered by NICE				
TA931: Zanubrutinib for treating chronic lymphocytic leukaemia	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA934: Foslevodopa–foscarnidopa for treating advanced Parkinson’s with motor symptoms	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA935: Secukinumab for treating moderate to severe hidradenitis suppurativa	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA937: Targeted-release budesonide for treating primary IgA nephropathy	RED			The formulary will reflect the TAG – currently awaiting ICB ratification
TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA942: Empagliflozin for treating chronic kidney disease	GREEN			ICS is the responsible commissioner.
HST29: Velmanase alfa for treating alpha-mannosidosis	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
5) Appeals against earlier decisions by the APC				
Nil this month				
6) Miscellaneous formulary decisions by the APC				
Nil this month				

The following guidelines were presented to and approved at the February 2024 meeting of the APC:

- IBD guidance
- Prescribing Anticoagulants including recommendations for NVAf (Amber guidance

DECISION SUMMARY

- Migraine and cluster headache (Amber guidance)
- Care Home use of Homely remedies and skin tears
- Symptom management in palliative care

The following Drug information leaflets were presented to and approved at the February 2024 meeting of the APC:

- Nil this month

The following shared care guidelines were presented to and approved at the February 2024 meeting of the APC:

- Nil this month

Other documents presented to and approved at the February 2024 meeting of the APC:

- Nil this month